![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Degron and Takeda will collaborate to utilize Degron's GlueXplorer® platform to identify, validate, and optimize molecular glue degraders for specific therapeutic targets selected by Takeda.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $1,200.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 23, 2024